SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for SNP rs2854116

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 The Influence of Apolipoprotein C3 Variants on Liver Steatosis and Serum Liver Enzyme Values in Obese Children

In the past decades, obesity in children is much more prevalent in the world. Given the increasing prevalence of pediatric obesity worldwide, fatty liver incidence is on the rise. Genetic variant in apolipoprotein C3 (APOC3) gene is associated with increased liver fat content in adults. The aim of this study is to find out whether APOC3 single nucleotide polymorphism (SNP) influence fatty liver in obese children and adolescent.

NCT01682655 Fatty Liver Obesity
MeSH: Fatty Liver
HPO: Hepatic steatosis

genotype distribution of APOC3 rs2854117 and rs2854116 polymorphisms in subjects with and without liver steatosis.

genotype distribution of APOC3 rs2854117 and rs2854116 polymorphisms in subjects with and without insulin resistance.

Inclusion Criteria: - Age 6-18 years old - Obesity definition: BMI > 95% according to the age- and gender-specific standard suggested by National Health Institute in Taiwan - Willing to give written informed consent by parents Exclusion Criteria: - Alcohol consumption - Chronic liver diseases, including hepatitis B, hepatitis C, Wilson disease and autoimmune hepatitis - Major systemic diseases, including cardiopulmonary disease, renal failure, cancer, and psychotic disorder Inclusion Criteria: - Age 6-18 years old - Obesity definition: BMI > 95% according to the age- and gender-specific standard suggested by National Health Institute in Taiwan - Willing to give written informed consent by parents Exclusion Criteria: - Alcohol consumption - Chronic liver diseases, including hepatitis B, hepatitis C, Wilson disease and autoimmune hepatitis - Major systemic diseases, including cardiopulmonary disease, renal failure, cancer, and psychotic disorder Fatty Liver Obesity Fatty Liver The primary aim of this study is to assess the associations between to investigate the association of rs2854117 C > T and rs2854116 T > C SNPs of the APOC3 gene with liver steatosis, as measured by liver ultrasound.

As a secondary aim, the investigators will examine the associations between APOC3 rs2854117 C > T and rs2854116 T > C SNPs and serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels.

Primary Outcomes

Measure: genotype distribution of APOC3 rs2854117 and rs2854116 polymorphisms in subjects with and without liver steatosis

Time: Oct 2013 ~ Dec 2014

Secondary Outcomes

Measure: genotype distribution of APOC3 rs2854117 and rs2854116 polymorphisms in subjects with and without insulin resistance

Time: Oct 2013 ~ Dec 2014


HPO Nodes


Hepatic steatosis
Genes 137
ATP7B LDLRAP1 MPV17 CLPB APOE APOB SLC40A1 POLG HNF1B COA8 ABCG8 BSCL2 HFE GPD1 BCS1L CIDEC ACAD9 LYRM4 AGPAT2 LMNA LMNB2 PRDM16 CAV1 FOS LMNA TYMP LIPE RERE BCS1L MPV17 BSCL2 CIDEC MCCC1 ACADM PLIN1 SLC25A13 HADHB ETFA CAV1 XRCC4 CPT1A FBP1 PCK1 PTRH2 CEP19 RMND1 LMNA GABRD POLR3A TMEM199 NSMCE2 PPARG ADK ACAD9 LIPA TFAM NGLY1 PMM2 HNRNPA1 VPS33A AKT2 POLD1 MARS1 DDOST TRAPPC11 ETFB ACADVL BSCL2 ALMS1 LMNA LARS1 CPT2 CBS CARS2 COX15 NDUFAF1 LRPPRC ALDOB PCSK9 HNRNPA2B1 TRMU PGM1 NSMCE2 CPT2 LIPE ACOX1 LDLR CYP7A1 MRPL44 PCK2 DNAJC19 LMNA FARSB ABHD5 CAVIN1 PNPLA2 HADH ZMPSTE24 ETFDH ALMS1 PNPLA2 SLC22A5 PHKG2 AGPAT2 DGUOK ATP6AP1 COG6 ABHD5 HADHA PHKA2 SLC40A1 TARS2 LMNA TRAPPC11 PPARG MRPS7 KCNAB2 ACADL HADH SLC25A13 ACADM VCP HNF4A PLIN1 PPARG EARS2 SAR1B CAVIN1 SLC25A13 HSD17B4 DNAJC19 RRM2B SKI CYP19A1 IARS1 POLG ABCG5